SCHEMBL30553444

SCHEMBL30553444

NC(=O)c1cccc(S(=O)(=O)Nc2ccc(N3CCOCC3)c3cccnc23)c1

nearest known ligand 0.72

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 8/20 0.72
▸ TDP1 Q9NUW8 1/20 0.55
▸ MMP2 P08253 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ SCN9A Q15858 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CREBBP Q92793 1/20 0.42
▸ CKS1B P61024 2/20 0.41
▸ SKP2 Q13309 2/20 0.41
▸ MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26964248 1.00 SLC40A1 (0.72) SLC40A1TDP1MMP2KDM4EALDH1A1
SCHEMBL11973035 0.84 SLC40A1 (1.00) SLC40A1TDP1MMP2ALDH1A1LMNA
SCHEMBL29800803 0.83 SLC40A1 (0.74) SLC40A1TDP1ALDH1A1LMNASCN9A
SCHEMBL26964203 0.83 SLC40A1 (0.74) SLC40A1TDP1ALDH1A1LMNASCN9A
SCHEMBL30553397 0.81 SLC40A1 (0.69) SLC40A1KDM4EALDH1A1MAPTLMNA
SCHEMBL17506516 0.80 SLC40A1 (0.82) SLC40A1TDP1KDM4EALDH1A1MAPT
SCHEMBL30553404 0.78 SLC40A1 (0.76) SLC40A1TDP1MMP2ALDH1A1LMNA
SCHEMBL26964435 0.78 SLC40A1 (0.76) SLC40A1TDP1MMP2ALDH1A1LMNA
SCHEMBL30925584 0.78 SLC40A1 (0.72) SLC40A1TDP1CKS1BSKP2MAPK1
SCHEMBL11973763 0.77 SLC40A1 (0.74) SLC40A1TDP1KDM4EMAPTCREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed
CN-116806218-A Sulfonamide and its use for the treatment of parasitic helminth infections and diseases 新基公司 2023-09-26 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC40A1 3357/4885TDP1 4247/4885MMP2 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback